Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer

I. Teles Alves, T. Hartjes, E. McClellan, S. Hiltemann, R. Böttcher, N. Dits, Ramzi Temanni, B. Janssen, W. Van Workum, P. Van Der Spek, A. Stubbs, A. De Klein, B. Eussen, J. Trapman, G. Jenster

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Gene fusions, mainly between TMPRSS2 and ERG, are frequent early genomic rearrangements in prostate cancer (PCa). In order to discover novel genomic fusion events, we applied whole-genome paired-end sequencing to identify structural alterations present in a primary PCa patient (G089) and in a PCa cell line (PC346C). Overall, we identified over 3800 genomic rearrangements in each of the two samples as compared with the reference genome. Correcting these structural variations for polymorphisms using whole-genome sequences of 46 normal samples, the numbers of cancer-related rearrangements were 674 and 387 for G089 and PC346C, respectively. From these, 192 in G089 and 106 in PC346C affected gene structures. Exclusion of small intronic deletions left 33 intergenic breaks in G089 and 14 in PC346C. Out of these, 12 and 9 reassembled genes with the same orientation, capable of generating a feasible fusion transcript. Using PCR we validated all the reliable predicted gene fusions. Two gene fusions were in-frame: MPP5-FAM71D in PC346C and ARHGEF3-C8ORF38 in G089. Downregulation of FAM71D and MPP5-FAM71D transcripts in PC346C cells decreased proliferation; however, no effect was observed in the RWPE-1-immortalized normal prostate epithelial cells. Together, our data showed that gene rearrangements frequently occur in PCa genomes but result in a limited number of fusion transcripts. Most of these fusion transcripts do not encode in-frame fusion proteins. The unique in-frame MPP5-FAM71D fusion product is important for proliferation of PC346C cells.

Original languageEnglish
Pages (from-to)568-577
Number of pages10
JournalOncogene
Volume34
Issue number5
DOIs
Publication statusPublished - 29 Jan 2015
Externally publishedYes

Fingerprint

Gene Fusion
Prostatic Neoplasms
Genome
Cell Proliferation
Gene Rearrangement
Genes
Prostate
Down-Regulation
Epithelial Cells
Cell Line
Polymerase Chain Reaction
Neoplasms
Proteins

Keywords

  • FAM71D
  • gene fusions
  • MPP5
  • next-generation sequencing
  • prostate cancer

ASJC Scopus subject areas

  • Medicine(all)
  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Teles Alves, I., Hartjes, T., McClellan, E., Hiltemann, S., Böttcher, R., Dits, N., ... Jenster, G. (2015). Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer. Oncogene, 34(5), 568-577. https://doi.org/10.1038/onc.2013.591

Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer. / Teles Alves, I.; Hartjes, T.; McClellan, E.; Hiltemann, S.; Böttcher, R.; Dits, N.; Temanni, Ramzi; Janssen, B.; Van Workum, W.; Van Der Spek, P.; Stubbs, A.; De Klein, A.; Eussen, B.; Trapman, J.; Jenster, G.

In: Oncogene, Vol. 34, No. 5, 29.01.2015, p. 568-577.

Research output: Contribution to journalArticle

Teles Alves, I, Hartjes, T, McClellan, E, Hiltemann, S, Böttcher, R, Dits, N, Temanni, R, Janssen, B, Van Workum, W, Van Der Spek, P, Stubbs, A, De Klein, A, Eussen, B, Trapman, J & Jenster, G 2015, 'Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer', Oncogene, vol. 34, no. 5, pp. 568-577. https://doi.org/10.1038/onc.2013.591
Teles Alves I, Hartjes T, McClellan E, Hiltemann S, Böttcher R, Dits N et al. Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer. Oncogene. 2015 Jan 29;34(5):568-577. https://doi.org/10.1038/onc.2013.591
Teles Alves, I. ; Hartjes, T. ; McClellan, E. ; Hiltemann, S. ; Böttcher, R. ; Dits, N. ; Temanni, Ramzi ; Janssen, B. ; Van Workum, W. ; Van Der Spek, P. ; Stubbs, A. ; De Klein, A. ; Eussen, B. ; Trapman, J. ; Jenster, G. / Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer. In: Oncogene. 2015 ; Vol. 34, No. 5. pp. 568-577.
@article{456bf7bf508a4a13a489f76205d5f8b9,
title = "Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer",
abstract = "Gene fusions, mainly between TMPRSS2 and ERG, are frequent early genomic rearrangements in prostate cancer (PCa). In order to discover novel genomic fusion events, we applied whole-genome paired-end sequencing to identify structural alterations present in a primary PCa patient (G089) and in a PCa cell line (PC346C). Overall, we identified over 3800 genomic rearrangements in each of the two samples as compared with the reference genome. Correcting these structural variations for polymorphisms using whole-genome sequences of 46 normal samples, the numbers of cancer-related rearrangements were 674 and 387 for G089 and PC346C, respectively. From these, 192 in G089 and 106 in PC346C affected gene structures. Exclusion of small intronic deletions left 33 intergenic breaks in G089 and 14 in PC346C. Out of these, 12 and 9 reassembled genes with the same orientation, capable of generating a feasible fusion transcript. Using PCR we validated all the reliable predicted gene fusions. Two gene fusions were in-frame: MPP5-FAM71D in PC346C and ARHGEF3-C8ORF38 in G089. Downregulation of FAM71D and MPP5-FAM71D transcripts in PC346C cells decreased proliferation; however, no effect was observed in the RWPE-1-immortalized normal prostate epithelial cells. Together, our data showed that gene rearrangements frequently occur in PCa genomes but result in a limited number of fusion transcripts. Most of these fusion transcripts do not encode in-frame fusion proteins. The unique in-frame MPP5-FAM71D fusion product is important for proliferation of PC346C cells.",
keywords = "FAM71D, gene fusions, MPP5, next-generation sequencing, prostate cancer",
author = "{Teles Alves}, I. and T. Hartjes and E. McClellan and S. Hiltemann and R. B{\"o}ttcher and N. Dits and Ramzi Temanni and B. Janssen and {Van Workum}, W. and {Van Der Spek}, P. and A. Stubbs and {De Klein}, A. and B. Eussen and J. Trapman and G. Jenster",
year = "2015",
month = "1",
day = "29",
doi = "10.1038/onc.2013.591",
language = "English",
volume = "34",
pages = "568--577",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer

AU - Teles Alves, I.

AU - Hartjes, T.

AU - McClellan, E.

AU - Hiltemann, S.

AU - Böttcher, R.

AU - Dits, N.

AU - Temanni, Ramzi

AU - Janssen, B.

AU - Van Workum, W.

AU - Van Der Spek, P.

AU - Stubbs, A.

AU - De Klein, A.

AU - Eussen, B.

AU - Trapman, J.

AU - Jenster, G.

PY - 2015/1/29

Y1 - 2015/1/29

N2 - Gene fusions, mainly between TMPRSS2 and ERG, are frequent early genomic rearrangements in prostate cancer (PCa). In order to discover novel genomic fusion events, we applied whole-genome paired-end sequencing to identify structural alterations present in a primary PCa patient (G089) and in a PCa cell line (PC346C). Overall, we identified over 3800 genomic rearrangements in each of the two samples as compared with the reference genome. Correcting these structural variations for polymorphisms using whole-genome sequences of 46 normal samples, the numbers of cancer-related rearrangements were 674 and 387 for G089 and PC346C, respectively. From these, 192 in G089 and 106 in PC346C affected gene structures. Exclusion of small intronic deletions left 33 intergenic breaks in G089 and 14 in PC346C. Out of these, 12 and 9 reassembled genes with the same orientation, capable of generating a feasible fusion transcript. Using PCR we validated all the reliable predicted gene fusions. Two gene fusions were in-frame: MPP5-FAM71D in PC346C and ARHGEF3-C8ORF38 in G089. Downregulation of FAM71D and MPP5-FAM71D transcripts in PC346C cells decreased proliferation; however, no effect was observed in the RWPE-1-immortalized normal prostate epithelial cells. Together, our data showed that gene rearrangements frequently occur in PCa genomes but result in a limited number of fusion transcripts. Most of these fusion transcripts do not encode in-frame fusion proteins. The unique in-frame MPP5-FAM71D fusion product is important for proliferation of PC346C cells.

AB - Gene fusions, mainly between TMPRSS2 and ERG, are frequent early genomic rearrangements in prostate cancer (PCa). In order to discover novel genomic fusion events, we applied whole-genome paired-end sequencing to identify structural alterations present in a primary PCa patient (G089) and in a PCa cell line (PC346C). Overall, we identified over 3800 genomic rearrangements in each of the two samples as compared with the reference genome. Correcting these structural variations for polymorphisms using whole-genome sequences of 46 normal samples, the numbers of cancer-related rearrangements were 674 and 387 for G089 and PC346C, respectively. From these, 192 in G089 and 106 in PC346C affected gene structures. Exclusion of small intronic deletions left 33 intergenic breaks in G089 and 14 in PC346C. Out of these, 12 and 9 reassembled genes with the same orientation, capable of generating a feasible fusion transcript. Using PCR we validated all the reliable predicted gene fusions. Two gene fusions were in-frame: MPP5-FAM71D in PC346C and ARHGEF3-C8ORF38 in G089. Downregulation of FAM71D and MPP5-FAM71D transcripts in PC346C cells decreased proliferation; however, no effect was observed in the RWPE-1-immortalized normal prostate epithelial cells. Together, our data showed that gene rearrangements frequently occur in PCa genomes but result in a limited number of fusion transcripts. Most of these fusion transcripts do not encode in-frame fusion proteins. The unique in-frame MPP5-FAM71D fusion product is important for proliferation of PC346C cells.

KW - FAM71D

KW - gene fusions

KW - MPP5

KW - next-generation sequencing

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84927171105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927171105&partnerID=8YFLogxK

U2 - 10.1038/onc.2013.591

DO - 10.1038/onc.2013.591

M3 - Article

VL - 34

SP - 568

EP - 577

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 5

ER -